DNA甲基化转移酶谱表达与肾透明细胞癌病理特征及预后的相关性  

Clinicopathological significance and prognostic analysis of DNA methyltransferase 1,3A and 3B expressions in clear cell renal cell carcinoma

作　　者：梁亮[1] 赵华才[1] 徐永刚[1] 高杨[1] 孙羿[1] 程永毅[1] 

机构地区：[1]陕西省人民医院泌尿外科,陕西西安710061

出　　处：《现代泌尿外科杂志》2017年第5期326-330,共5页Journal of Modern Urology

基　　金：国家自然科学基金青年项目(No.81502205);陕西省自然基础研究计划青年项目(No.2014JQ4157)

摘　　要：目的明确DNA甲基化转移酶家族(DNMTs)表达(DNMT1,DNMT3A及DNMT3B)与肾透明细胞癌患者病理特征及患者预后的相关性。方法收集本院2006-2014年行手术治疗并术后病理证实为透明细胞癌患者肿瘤及对应癌旁标本(90例),术后随访时间为18~90个月,应用免疫组织化学方法检测DNMTs表达状况,分析DNMTs表达与肾透明细胞癌临床病理特征及患者预后的关系。结果 DNMTs在肾透明细胞癌组织中表达强度显著高于正常肾脏组织(P<0.001);DNMTs表达强度与肿瘤大小(P<0.01)、病理分级(P<0.01)、临床分期(P<0.05)关系密切,而与患者性别、年龄未见显著性差异(P>0.01);DNMTs表达强度与患者总生存时间(OS)呈负相关性(P<0.001)。结论 DNMTs表达与透明细胞癌患者病理特征及预后关系密切,其表达异常升高可能是透明细胞癌发生发展的重要原因,并有可能作为透明细胞癌早期监测指标及治疗靶点。ObjectiveTo explore the correlation between expression of DNA methyltransferase family （DNMT1/3A/3B） and the clinicopathological characteristics and prognosis of clear cell renal cell carcinoma （ccRCC）. MethodsA total 90 ccRCC tissues and adjacent normal tissues were collected. All patients were followed up for 18-90 months. The expressions of DNMT1, DNMT3A and DNMT3B （DNMTs） were detected with immunohistochemical method. The correlation between DNMTs expressions and the clinicopathological characteristics and prognosis of ccRCC was analyzed. ResultsDNMTs were highly expressed in ccRCC than in non-tumor tissues （all P〈0.001）. DNMTs expressions were significantly related to tumor size （all P〈0.01）, pathological grading （all P〈0.01） and clinical staging （all P〈0.05）, but not related to age or gender （all P〉0.01）. The Kaplan-Meier survival analysis demonstrated the DNMTs expressions significantly associated with overall survival （all P〈0.001）. ConclusionDNMTs are highly expressed in ccRCC tumor than adjacent non-tumor tissue, which are strongly associated with clinicopathology and prognosis. DNMTs may be a prognostic and therapeutic target for ccRCC.

关 键 词：肾透明细胞癌 DNA甲基化转移酶 DNA甲基化 表观遗传学 

分 类 号：R737.11[医药卫生—肿瘤]